# Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis

> **NCT04532710** · PHASE2 · COMPLETED · sponsor: **Marinomed Biotech AG** · enrollment: 64 (actual)

## Conditions studied

- Allergic Conjunctivitis
- Allergic Rhinitis

## Interventions

- **DRUG:** Eye Drops, Solution in Single-Dose Container

## Key facts

- **NCT ID:** NCT04532710
- **Lead sponsor:** Marinomed Biotech AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-04
- **Primary completion:** 2021-05-27
- **Final completion:** 2021-05-27
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2022-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04532710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04532710, "Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04532710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*